Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults)

NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical

SPS commentary:

This alert is supported by UK Interim Clinical Commissioning Policies for tocilizumab and sarilumab which describe the criteria for use and exclusion criteria in detail.

Source:

Medicines and Healthcare products Regulatory Agency

Resource links:

Interim Clinical Commissioning Policy: Tocilizumab

Interim Clinical Commissioning Policy: Sarilumab